agents[J].Circulation,1997,95(8):2007-2014.[4]TheALLHATofficersandcoordinatorsfortheALLHATCollaborativeResearchGroup.MajoroutcomesinhighriskhypertensivepatientsrandomizedtoACEinhibitoracalciumchannelblockervsdiuretictheantihypertensiveandlipidlowering.Treatmenttopreventheartattacktrial(ALLHAT)[J].JAMA,2002,288(23):2981-2997.[5]吴立萱,金凡,黄元伟.氨氯地平抑制氧化修饰低密度脂蛋白诱导的血管平滑肌细胞增殖[J].中华心血管病杂志,2003,31(5):378.米氮平与阿普唑仑治疗慢性失眠症的临床疗效比较李琼芝,江金香(浙江省丽水市人民医院医学心理科,323000)[摘要]目的比较米氮平与阿普唑仑治疗慢性失眠症的临床效果。方法慢性失眠症患者79例,分成治疗组38例,对照组41例。治疗组睡前30min口服米氮平10~15mg;对照组睡前30min口服阿普唑仑0.4~0.8mg,12周为1个疗程。采用匹兹堡睡眠指数(PSQI)及睡眠日记分别在治疗前和治疗后第4,8和12周评定疗效。结果治疗组总有效率96.9%,显效率90.6%,对照组则分别为78.8%和51.5%,治疗组显效率高于对照组(P<0.05)。治疗组主要不良反应有嗜睡、头昏、体重增加等。结论米氮平治疗慢性失眠症疗效确切,不良反应轻微,开始宜小剂量使用。[关键词]米氮平;阿普唑仑;失眠症,慢性[中图分类号]R971.43;R749.4[文献标识码]A[文章编号]10040781(2006)09090703ComparisonofTherapeuticEffectsbetweenMirtazapineandAlprazolamonChronicInsomniaLIQiongzhi,JIANGJinxiang(DepartmentofPsychology,thePeople’sHospitalofLishuiCity,ZhejiangProvince,Lishui323000,China)ABSTRACTObjectiveTodeterminewhethermirtazapinneisclinicallyeffectiveonthetreatmentofchronicinsomniaandtocomparetheclinicaleffectsbetweenmirtazapineandalpazolamonchronicinsomnia.MethodsSeventyninepatientswererandomlydividedintotwogroups(38and41foreach),whichreceivedthetreatmentsofmirtazapineandalprazolamrespectivelyfor12weeksasacourse.Thepatientsinmirtazapinegrouptook10-15mg0.5hourbeforesleeping,whilethepatientsinalpazolamgrouptook0.4-0.8mg0.5hourbeforesleeping.ThecurativeeffectswereevaluatedwithPittsburghSleepQualityIndex(PSQI)andsleepingdairybeforeandafterthe4th,8th,and12thweeksoftreatment.ResultsTheeffectiverateandsignificantlyeffectiverateofmirtaza...